Ilustração: Marta Pucci

DIU: o que é, mitos, como é inserido e funcionamento

Saiba tudo sobre um dos métodos mais eficazes para evitar gravidez

von Giordana Braga — April 3, 2019 Medizinisch überprüft von Laurie Ray, DNP

Lebe im Einklang mit deinem Zyklus und lade die Clue App noch heute herunter.

Apple Store

Google Play

Literaturhinweise

Trussell J. Contraceptive failure in the United States. Contraception. 2011 May;83(5):397–404.
Ministério da Saúde do Brasil. Pesquisa Nacional de Demografia e Saúde da criança e da Mulher - PNDS 2006. Available from: bvsms.saude.gov.br/bvs/publicacoes/pnds_crianca_mulher.pdf
Buhling KJ, Hauck B, Dermout S, Ardaens K, Marions L. Understanding the barriers and myths limiting the use of intrauterine contraception in nulliparous women: results of a survey of European/Canadian healthcare providers. Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:146–54.
Buhling KJ, Lotke P, Black K, INTRA Writing Group. Worldwide use of intrauterine contraception: a review. Contraception 2014 ;89(3):162-73.
Silva-Filho AL, Lira J, Rocha AL, Ferreira MC, Lamaita RM, Candido EB, CArneiro MM. Non-hormonal and hormonal intrauterine contraception: survey of patients’ perceptions in four Latin American countries.European Journal of Reproductive Health Care, 2016;21(3):213-9.
Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. 2007 Jun;75(6 Suppl):S16-30.
Wildemeersch D. Commentary - Lyus R, Lohr P, Prager S. Use of Mirena LNG-IUS and Paragard CuT380A intrauterine devices for nulliparous women [Contraception 2010;81:367-371]. Contraception. 2011 Feb;83(2):184-186-187.
WHO elegibility criteria for contraceptive use, 5th edition, 2015.
Bahamondes MV, Hidalgo MM, Bahamondes L, Monteiro I. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception. 2011 Nov;84(5):e11-16.
Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet Lond Engl. 1992 Mar 28;339(8796):785–8.
Black KI, Lotke P, Lira J, Peers T, Zite NB. Global survey of healthcare practitioners’ beliefs and practices around intrauterine contraceptive method use in nulliparous women. Contraception. 2013 Nov;88(5):650–6.
Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S, et al. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod Oxf Engl. 2015 Nov;30(11):2527–38.
Jensen J, Mansour D, Lukkari-Lax E, Inki P, Burock K, Fraser IS. Bleeding patterns with the levonorgestrel-releasing intrauterine system when used for heavy menstrual bleeding in women without structural pelvic pathology: a pooled analysis of randomized controlled studies. Contraception. 2013 Jan;87(1):107–12.
Bosanac SS, Trivedi M, Clark AK, Sivamani RK, Larsen LN. Progestins and acne vulgaris: a review. Dermmaology Online Journal. 2018 15;24(5).